RESUMO
Hormone-dependent cancers including prostatic cancer respond to endocrine therapy in initial phase, but gradually loss responsiveness and eventually show autonomous growth despite of continuation or the treatment At present it is difficult to predict on an individual basis who will respond to hormonal therapy and for how long. If unresponsive patient could be identified. they could be treated by alternative forms of therapy (e.g., chemotherapy). Thus there is a great need to predict the quality and duration of response to endocrine manipulation. Recently androgen receptor assay and other methods to predict the responsiveness of prostatic cancer to androgen ablation therapy have been developed. We studied androgen receptor, RNA polymerase activity and chromosome analysis on the androgen-responsive Shionogi Carcinoma 115 (SC115} cells and established a pure androgen-dependent cancer cell line from this tumor.